Truqap

Overview

capivasertib

kinase inhibitor

• CYP3A4 substrate
• CYP2D6 inhibitor, moderate
• CYP3A4 inhibitor, weak
• UGT1A1 inhibitor
• hyperglycemic effects

Contraindicated

• cisapride
Truqap (capivasertib)

+

cisapride

1 interaction

Contraindicated

capivasertib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• eliglustat
Truqap (capivasertib)

+

eliglustat

1 interaction

Contraindicated

capivasertib + eliglustat

CYP2D6 EXTENSIVE METABOLIZERS: contraindicated if Child-Pugh Class A; otherwise, consider alternative or monitor ECG, decr. eliglustat dose to 84 mg qd; CYP2D6 INTERMEDIATE METABOLIZERS: consider alternative or monitor ECG, decr. eliglustat dose to 84 mg qd; CYP2D6 POOR METABOLIZERS: avoid combo: combo may incr. eliglustat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• thioridazine
Truqap (capivasertib)

+

thioridazine

1 interaction

Contraindicated

capivasertib + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

Avoid/Use Alternative

• adagrasib
Truqap (capivasertib)

+

adagrasib

1 interaction

Avoid/Use Alternative

capivasertib + adagrasib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• alprazolam
Truqap (capivasertib)

+

alprazolam

1 interaction

Avoid/Use Alternative

capivasertib + alprazolam

use alternative or monitor resp. rate, glucose; consider decr. alprazolam dose: combo may incr. levels of both drugs, risk of CNS and resp. depression, psychomotor impairment, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• apalutamide
Truqap (capivasertib)

+

apalutamide

1 interaction

Avoid/Use Alternative

capivasertib + apalutamide

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• atazanavir
Truqap (capivasertib)

+

atazanavir

1 interaction

Avoid/Use Alternative

capivasertib + atazanavir

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• belinostat
Truqap (capivasertib)

+

belinostat

1 interaction

Avoid/Use Alternative

capivasertib + belinostat

use alternative or monitor CBC; decr. belinostat dose as follows: if on belinostat 1000 mg^m2, decr. to 750 mg^m2; if on belinostat 750 mg^m2, decr. to 562.5 mg/m^2; if on belinostat 500 mg/m^2, hold belinostat during capivasertib use: combo may incr. belinostat levels, risk of serious infection, myelosuppression, other adverse effects (UGT inhibited)

• bosentan
Truqap (capivasertib)

+

bosentan

1 interaction

Avoid/Use Alternative

capivasertib + bosentan

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• butalbital
Truqap (capivasertib)

+

butalbital

1 interaction

Avoid/Use Alternative

capivasertib + butalbital

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• carbamazepine
Truqap (capivasertib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

capivasertib + carbamazepine

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. carbamazepine levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• cenobamate
Truqap (capivasertib)

+

cenobamate

1 interaction

Avoid/Use Alternative

capivasertib + cenobamate

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• ceritinib
Truqap (capivasertib)

+

ceritinib

1 interaction

Avoid/Use Alternative

capivasertib + ceritinib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• chloramphenicol
Truqap (capivasertib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

capivasertib + chloramphenicol

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• clarithromycin
Truqap (capivasertib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

capivasertib + clarithromycin

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• cobicistat
Truqap (capivasertib)

+

cobicistat

1 interaction

Avoid/Use Alternative

capivasertib + cobicistat

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• codeine
Truqap (capivasertib)

+

codeine

1 interaction

Avoid/Use Alternative

capivasertib + codeine

use alternative or monitor resp. rate, withdrawal sx; consider decr. codeine dose: combo may incr. codeine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may incr. or decr. active metabolite morphine levels, incr. risk of CNS and resp. depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metab. inhibited, may incr. or decr. production of active metabolite morphine)

• colchicine
Truqap (capivasertib)

+

colchicine

1 interaction

Avoid/Use Alternative

capivasertib + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT or FMF: use alternative or consider decr. colchicine dose during and x14 days after capivasertib use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited)

• dabrafenib
Truqap (capivasertib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

capivasertib + dabrafenib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• dihydrocodeine
Truqap (capivasertib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

capivasertib + dihydrocodeine

use alternative or monitor resp. rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metab. inhibited, decr. conversion to dihydromorphine)

• doxorubicin
Truqap (capivasertib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

capivasertib + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metab. inhibited)

• efavirenz
Truqap (capivasertib)

+

efavirenz

1 interaction

Avoid/Use Alternative

capivasertib + efavirenz

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• encorafenib
Truqap (capivasertib)

+

encorafenib

1 interaction

Avoid/Use Alternative

capivasertib + encorafenib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• enzalutamide
Truqap (capivasertib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

capivasertib + enzalutamide

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• etravirine
Truqap (capivasertib)

+

etravirine

1 interaction

Avoid/Use Alternative

capivasertib + etravirine

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• fexinidazole
Truqap (capivasertib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

capivasertib + fexinidazole

avoid combo: combo may decr. capivasertib levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metab. induced; hepatic metab. inhibited, decr. conversion to active metabolites)

• fosamprenavir
Truqap (capivasertib)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

capivasertib + fosamprenavir

consider alternative: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metab. altered)

• fosphenytoin
Truqap (capivasertib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

capivasertib + fosphenytoin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• grapefruit
Truqap (capivasertib)

+

grapefruit

1 interaction

Avoid/Use Alternative

capivasertib + grapefruit

avoid combo: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metab. inhibited)

• hydrocodone
Truqap (capivasertib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

capivasertib + hydrocodone

use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• idelalisib
Truqap (capivasertib)

+

idelalisib

1 interaction

Avoid/Use Alternative

capivasertib + idelalisib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• irinotecan
Truqap (capivasertib)

+

irinotecan

1 interaction

Avoid/Use Alternative

capivasertib + irinotecan

use alternative: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (UGT inhibited)

• itraconazole
Truqap (capivasertib)

+

itraconazole

1 interaction

Avoid/Use Alternative

capivasertib + itraconazole

during and x2wk after itraconazole tx, use alternative or monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ivosidenib
Truqap (capivasertib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

capivasertib + ivosidenib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• ketoconazole
Truqap (capivasertib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

capivasertib + ketoconazole

during and up to 1wk after ketoconazole tx, use alternative or monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lenacapavir
Truqap (capivasertib)

+

lenacapavir

1 interaction

Avoid/Use Alternative

capivasertib + lenacapavir

avoid combo if also combined w/ strong CYP3A4 and P-gp inhibitors; otherwise, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off during and x9mo after lenacapavir tx: combo may incr. level of both drugs, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited, UGT inhibited)

• levoketoconazole
Truqap (capivasertib)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

capivasertib + levoketoconazole

use alternative or monitor glucose, consider monitoring ECG; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lisdexamfetamine
Truqap (capivasertib)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

capivasertib + lisdexamfetamine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• lonafarnib
Truqap (capivasertib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

capivasertib + lonafarnib

use alternative or monitor glucose, HR, ECG, electrolytes; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lopinavir/ritonavir
Truqap (capivasertib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

capivasertib + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metab. altered)

• lorlatinib
Truqap (capivasertib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

capivasertib + lorlatinib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• lumacaftor/ivacaftor
Truqap (capivasertib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

capivasertib + lumacaftor/ ivacaftor

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• mavacamten
Truqap (capivasertib)

+

mavacamten

1 interaction

Avoid/Use Alternative

capivasertib + mavacamten

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• meperidine
Truqap (capivasertib)

+

meperidine

1 interaction

Avoid/Use Alternative

capivasertib + meperidine

use alternative or monitor resp. rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• methadone
Truqap (capivasertib)

+

methadone

1 interaction

Avoid/Use Alternative

capivasertib + methadone

use alternative or monitor resp. rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• mifepristone
Truqap (capivasertib)

+

mifepristone

1 interaction

Avoid/Use Alternative

capivasertib + mifepristone

during and x14 days after daily mifepristone use, use alternative or monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• mitapivat
Truqap (capivasertib)

+

mitapivat

1 interaction

Avoid/Use Alternative

capivasertib + mitapivat

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• mitotane
Truqap (capivasertib)

+

mitotane

1 interaction

Avoid/Use Alternative

capivasertib + mitotane

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• modafinil
Truqap (capivasertib)

+

modafinil

1 interaction

Avoid/Use Alternative

capivasertib + modafinil

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• nafcillin
Truqap (capivasertib)

+

nafcillin

1 interaction

Avoid/Use Alternative

capivasertib + nafcillin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• nefazodone
Truqap (capivasertib)

+

nefazodone

1 interaction

Avoid/Use Alternative

capivasertib + nefazodone

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• nelfinavir
Truqap (capivasertib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

capivasertib + nelfinavir

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• oliceridine
Truqap (capivasertib)

+

oliceridine

1 interaction

Avoid/Use Alternative

capivasertib + oliceridine

use alternative or monitor resp. rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• oxycodone
Truqap (capivasertib)

+

oxycodone

1 interaction

Avoid/Use Alternative

capivasertib + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pacritinib
Truqap (capivasertib)

+

pacritinib

1 interaction

Avoid/Use Alternative

capivasertib + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects; may decr. capivasertib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• pentobarbital
Truqap (capivasertib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

capivasertib + pentobarbital

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• pexidartinib
Truqap (capivasertib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

capivasertib + pexidartinib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• phenobarbital
Truqap (capivasertib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

capivasertib + phenobarbital

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• phenytoin
Truqap (capivasertib)

+

phenytoin

1 interaction

Avoid/Use Alternative

capivasertib + phenytoin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• pimozide
Truqap (capivasertib)

+

pimozide

1 interaction

Avoid/Use Alternative

capivasertib + pimozide

avoid combo: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pirfenidone
Truqap (capivasertib)

+

pirfenidone

1 interaction

Avoid/Use Alternative

capivasertib + pirfenidone

avoid combo if also combined w/ mod-strong CYP1A2 inhibitor; otherwise, caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

• posaconazole
Truqap (capivasertib)

+

posaconazole

1 interaction

Avoid/Use Alternative

capivasertib + posaconazole

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• pralsetinib
Truqap (capivasertib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

capivasertib + pralsetinib

if also combined w/ P-gp inhibitor, use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd; otherwise, consider monitoring ECG, electrolytes: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• primidone
Truqap (capivasertib)

+

primidone

1 interaction

Avoid/Use Alternative

capivasertib + primidone

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• propafenone
Truqap (capivasertib)

+

propafenone

1 interaction

Avoid/Use Alternative

capivasertib + propafenone

avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited)

• repotrectinib
Truqap (capivasertib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

capivasertib + repotrectinib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• ribociclib
Truqap (capivasertib)

+

ribociclib

1 interaction

Avoid/Use Alternative

capivasertib + ribociclib

use alternative or monitor glucose, ECG, electrolytes, CBC; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• rifabutin
Truqap (capivasertib)

+

rifabutin

1 interaction

Avoid/Use Alternative

capivasertib + rifabutin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• rifampin
Truqap (capivasertib)

+

rifampin

1 interaction

Avoid/Use Alternative

capivasertib + rifampin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• rifapentine
Truqap (capivasertib)

+

rifapentine

1 interaction

Avoid/Use Alternative

capivasertib + rifapentine

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• ritonavir
Truqap (capivasertib)

+

ritonavir

1 interaction

Avoid/Use Alternative

capivasertib + ritonavir

consider alternative: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metab. altered)

• sacituzumab govitecan
Truqap (capivasertib)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

capivasertib + sacituzumab govitecan

avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

• simvastatin
Truqap (capivasertib)

+

simvastatin

1 interaction

Avoid/Use Alternative

capivasertib + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sotorasib
Truqap (capivasertib)

+

sotorasib

1 interaction

Avoid/Use Alternative

capivasertib + sotorasib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• St. John's wort
Truqap (capivasertib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

capivasertib + St. John's wort

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• tamsulosin
Truqap (capivasertib)

+

tamsulosin

1 interaction

Avoid/Use Alternative

capivasertib + tamsulosin

avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited)

• tipranavir
Truqap (capivasertib)

+

tipranavir

1 interaction

Avoid/Use Alternative

capivasertib + tipranavir

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• tramadol
Truqap (capivasertib)

+

tramadol

1 interaction

Avoid/Use Alternative

capivasertib + tramadol

use alternative or monitor resp. rate, ECG, withdrawal sx: combo may incr. tramadol levels, risk of CNS and resp. depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metab. inhibited, decr. conversion to active metabolite)

• tucatinib
Truqap (capivasertib)

+

tucatinib

1 interaction

Avoid/Use Alternative

capivasertib + tucatinib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• voriconazole
Truqap (capivasertib)

+

voriconazole

1 interaction

Avoid/Use Alternative

capivasertib + voriconazole

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

Monitor/Modify Tx

• abemaciclib
Truqap (capivasertib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

capivasertib + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Truqap (capivasertib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

capivasertib + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• acarbose
Truqap (capivasertib)

+

acarbose

1 interaction

Monitor/Modify Tx

capivasertib + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acetaminophen
Truqap (capivasertib)

+

acetaminophen

1 interaction

Monitor/Modify Tx

capivasertib + acetaminophen

consider acetaminophen dose adjustment: combo may incr. acetaminophen levels, risk of adverse effects (UGT inhibited)

• alfentanil
Truqap (capivasertib)

+

alfentanil

1 interaction

Monitor/Modify Tx

capivasertib + alfentanil

monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• alogliptin
Truqap (capivasertib)

+

alogliptin

1 interaction

Monitor/Modify Tx

capivasertib + alogliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• amiodarone
Truqap (capivasertib)

+

amiodarone

1 interaction

Monitor/Modify Tx

capivasertib + amiodarone

monitor ECG, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• amlodipine
Truqap (capivasertib)

+

amlodipine

1 interaction

Monitor/Modify Tx

capivasertib + amlodipine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• aprepitant
Truqap (capivasertib)

+

aprepitant

1 interaction

Monitor/Modify Tx

capivasertib + aprepitant

if aprepitant 3-day regimen, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off; aprepitant single dose-regimen OK: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• aripiprazole bimonthly injection
Truqap (capivasertib)

+

aripiprazole bimonthly injection

1 interaction

Monitor/Modify Tx

capivasertib + aripiprazole bimonthly injection

if also combined w/ strong CYP3A4 inhibitor and concurrent use >14 days, consider decr. aripiprazole dose to 720 mg q2mo: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• aripiprazole oral
Truqap (capivasertib)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

capivasertib + aripiprazole oral

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• asciminib
Truqap (capivasertib)

+

asciminib

1 interaction

Monitor/Modify Tx

capivasertib + asciminib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• atorvastatin
Truqap (capivasertib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

capivasertib + atorvastatin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• avacopan
Truqap (capivasertib)

+

avacopan

1 interaction

Monitor/Modify Tx

capivasertib + avacopan

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• avanafil
Truqap (capivasertib)

+

avanafil

1 interaction

Monitor/Modify Tx

capivasertib + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avapritinib
Truqap (capivasertib)

+

avapritinib

1 interaction

Monitor/Modify Tx

capivasertib + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• belumosudil
Truqap (capivasertib)

+

belumosudil

1 interaction

Monitor/Modify Tx

capivasertib + belumosudil

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• berberine
Truqap (capivasertib)

+

berberine

1 interaction

Monitor/Modify Tx

capivasertib + berberine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• berotralstat
Truqap (capivasertib)

+

berotralstat

1 interaction

Monitor/Modify Tx

capivasertib + berotralstat

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• bexagliflozin
Truqap (capivasertib)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + bexagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• bicalutamide
Truqap (capivasertib)

+

bicalutamide

1 interaction

Monitor/Modify Tx

capivasertib + bicalutamide

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• brexpiprazole
Truqap (capivasertib)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

capivasertib + brexpiprazole

if also combined w/ moderate or strong CYP3A4 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• brigatinib
Truqap (capivasertib)

+

brigatinib

1 interaction

Monitor/Modify Tx

capivasertib + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• bromocriptine
Truqap (capivasertib)

+

bromocriptine

1 interaction

Monitor/Modify Tx

capivasertib + bromocriptine

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• canagliflozin
Truqap (capivasertib)

+

canagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + canagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• chlorzoxazone
Truqap (capivasertib)

+

chlorzoxazone

1 interaction

Monitor/Modify Tx

capivasertib + chlorzoxazone

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• cilostazol
Truqap (capivasertib)

+

cilostazol

1 interaction

Monitor/Modify Tx

capivasertib + cilostazol

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• cimetidine
Truqap (capivasertib)

+

cimetidine

1 interaction

Monitor/Modify Tx

capivasertib + cimetidine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ciprofloxacin
Truqap (capivasertib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

capivasertib + ciprofloxacin

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• clofazimine
Truqap (capivasertib)

+

clofazimine

1 interaction

Monitor/Modify Tx

capivasertib + clofazimine

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• clotrimazole oropharyngeal
Truqap (capivasertib)

+

clotrimazole oropharyngeal

1 interaction

Monitor/Modify Tx

capivasertib + clotrimazole oropharyngeal

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• clozapine
Truqap (capivasertib)

+

clozapine

1 interaction

Monitor/Modify Tx

capivasertib + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metab. inhibited)

• colesevelam
Truqap (capivasertib)

+

colesevelam

1 interaction

Monitor/Modify Tx

capivasertib + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• conivaptan
Truqap (capivasertib)

+

conivaptan

1 interaction

Monitor/Modify Tx

capivasertib + conivaptan

during and x7 days after conivaptan tx, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. level of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• cranberry
Truqap (capivasertib)

+

cranberry

1 interaction

Monitor/Modify Tx

capivasertib + cranberry

monitor glucose, especially w/ large amounts of cranberry: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metab. inhibited)

• crizotinib
Truqap (capivasertib)

+

crizotinib

1 interaction

Monitor/Modify Tx

capivasertib + crizotinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• cyclosporine
Truqap (capivasertib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

capivasertib + cyclosporine

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• danazol
Truqap (capivasertib)

+

danazol

1 interaction

Monitor/Modify Tx

capivasertib + danazol

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• dapagliflozin
Truqap (capivasertib)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + dapagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• daridorexant
Truqap (capivasertib)

+

daridorexant

1 interaction

Monitor/Modify Tx

capivasertib + daridorexant

monitor glucose: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• darunavir
Truqap (capivasertib)

+

darunavir

1 interaction

Monitor/Modify Tx

capivasertib + darunavir

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• desipramine
Truqap (capivasertib)

+

desipramine

1 interaction

Monitor/Modify Tx

capivasertib + desipramine

monitor desipramine levels, ECG: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• deutetrabenazine
Truqap (capivasertib)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

capivasertib + deutetrabenazine

monitor ECG: combo may incr. deutetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• dextroamphetamine
Truqap (capivasertib)

+

dextroamphetamine

1 interaction

Monitor/Modify Tx

capivasertib + dextroamphetamine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• diltiazem
Truqap (capivasertib)

+

diltiazem

1 interaction

Monitor/Modify Tx

capivasertib + diltiazem

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• diosmin
Truqap (capivasertib)

+

diosmin

1 interaction

Monitor/Modify Tx

capivasertib + diosmin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• disopyramide
Truqap (capivasertib)

+

disopyramide

1 interaction

Monitor/Modify Tx

capivasertib + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• docetaxel
Truqap (capivasertib)

+

docetaxel

1 interaction

Monitor/Modify Tx

capivasertib + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dofetilide
Truqap (capivasertib)

+

dofetilide

1 interaction

Monitor/Modify Tx

capivasertib + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• domperidone
Truqap (capivasertib)

+

domperidone

1 interaction

Monitor/Modify Tx

capivasertib + domperidone

monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• dronedarone
Truqap (capivasertib)

+

dronedarone

1 interaction

Monitor/Modify Tx

capivasertib + dronedarone

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• dulaglutide
Truqap (capivasertib)

+

dulaglutide

1 interaction

Monitor/Modify Tx

capivasertib + dulaglutide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• duvelisib
Truqap (capivasertib)

+

duvelisib

1 interaction

Monitor/Modify Tx

capivasertib + duvelisib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• empagliflozin
Truqap (capivasertib)

+

empagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + empagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• entrectinib
Truqap (capivasertib)

+

entrectinib

1 interaction

Monitor/Modify Tx

capivasertib + entrectinib

monitor ECG, CBC, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ertugliflozin
Truqap (capivasertib)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

capivasertib + ertugliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• erythromycin
Truqap (capivasertib)

+

erythromycin

1 interaction

Monitor/Modify Tx

capivasertib + erythromycin

monitor ECG, glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• estradiol (contraceptive)
Truqap (capivasertib)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

capivasertib + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (UGT inhibited)

• ethinyl estradiol (contraceptive)
Truqap (capivasertib)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

capivasertib + ethinyl estradiol (contraceptive)

monitor glucose, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of severe hyperglycemia, thromboembolism, other adverse effects (hepatic metab. inhibited, UGT inhibited)

• everolimus
Truqap (capivasertib)

+

everolimus

1 interaction

Monitor/Modify Tx

capivasertib + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC, glucose; OTHER INDICATIONS: monitor CBC, glucose: combo may incr. levels of both drugs, risk of myelosuppression, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• exenatide
Truqap (capivasertib)

+

exenatide

1 interaction

Monitor/Modify Tx

capivasertib + exenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• fedratinib
Truqap (capivasertib)

+

fedratinib

1 interaction

Monitor/Modify Tx

capivasertib + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs; otherwise, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of myelosuppression, hepatotoxicity, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• felodipine
Truqap (capivasertib)

+

felodipine

1 interaction

Monitor/Modify Tx

capivasertib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• fentanyl
Truqap (capivasertib)

+

fentanyl

1 interaction

Monitor/Modify Tx

capivasertib + fentanyl

monitor resp. rate; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• finerenone
Truqap (capivasertib)

+

finerenone

1 interaction

Monitor/Modify Tx

capivasertib + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• flecainide
Truqap (capivasertib)

+

flecainide

1 interaction

Monitor/Modify Tx

capivasertib + flecainide

monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• flibanserin
Truqap (capivasertib)

+

flibanserin

1 interaction

Monitor/Modify Tx

capivasertib + flibanserin

monitor glucose, BP especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• fluconazole
Truqap (capivasertib)

+

fluconazole

1 interaction

Monitor/Modify Tx

capivasertib + fluconazole

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• fluvoxamine
Truqap (capivasertib)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

capivasertib + fluvoxamine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• fosaprepitant
Truqap (capivasertib)

+

fosaprepitant

1 interaction

Monitor/Modify Tx

capivasertib + fosaprepitant

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• fostamatinib
Truqap (capivasertib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

capivasertib + fostamatinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• gepirone
Truqap (capivasertib)

+

gepirone

1 interaction

Monitor/Modify Tx

capivasertib + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ginkgo
Truqap (capivasertib)

+

ginkgo

1 interaction

Monitor/Modify Tx

capivasertib + ginkgo

monitor glucose: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metab. altered)

• givinostat
Truqap (capivasertib)

+

givinostat

1 interaction

Monitor/Modify Tx

capivasertib + givinostat

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metab. inhibited)

• givosiran
Truqap (capivasertib)

+

givosiran

1 interaction

Monitor/Modify Tx

capivasertib + givosiran

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited, givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glecaprevir
Truqap (capivasertib)

+

glecaprevir

1 interaction

Monitor/Modify Tx

capivasertib + glecaprevir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• glimepiride
Truqap (capivasertib)

+

glimepiride

1 interaction

Monitor/Modify Tx

capivasertib + glimepiride

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Truqap (capivasertib)

+

glipizide

1 interaction

Monitor/Modify Tx

capivasertib + glipizide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Truqap (capivasertib)

+

glyburide

1 interaction

Monitor/Modify Tx

capivasertib + glyburide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• goldenseal
Truqap (capivasertib)

+

goldenseal

1 interaction

Monitor/Modify Tx

capivasertib + goldenseal

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• grazoprevir
Truqap (capivasertib)

+

grazoprevir

1 interaction

Monitor/Modify Tx

capivasertib + grazoprevir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ibrutinib
Truqap (capivasertib)

+

ibrutinib

1 interaction

Monitor/Modify Tx

capivasertib + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• iloperidone
Truqap (capivasertib)

+

iloperidone

1 interaction

Monitor/Modify Tx

capivasertib + iloperidone

monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• imatinib
Truqap (capivasertib)

+

imatinib

1 interaction

Monitor/Modify Tx

capivasertib + imatinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• imipramine
Truqap (capivasertib)

+

imipramine

1 interaction

Monitor/Modify Tx

capivasertib + imipramine

monitor imipramine levels: combo may incr. imipramine levels, risk of adverse effects (hepatic metab. inhibited)

• infigratinib
Truqap (capivasertib)

+

infigratinib

1 interaction

Monitor/Modify Tx

capivasertib + infigratinib

monitor phosphate: combo may incr. infigratinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• insulin
Truqap (capivasertib)

+

insulin

1 interaction

Monitor/Modify Tx

capivasertib + insulin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• isavuconazonium
Truqap (capivasertib)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

capivasertib + isavuconazonium

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• isoniazid
Truqap (capivasertib)

+

isoniazid

1 interaction

Monitor/Modify Tx

capivasertib + isoniazid

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• istradefylline
Truqap (capivasertib)

+

istradefylline

1 interaction

Monitor/Modify Tx

capivasertib + istradefylline

monitor glucose, especially w/ istradefylline 40 mg dose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ivabradine
Truqap (capivasertib)

+

ivabradine

1 interaction

Monitor/Modify Tx

capivasertib + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ivacaftor
Truqap (capivasertib)

+

ivacaftor

1 interaction

Monitor/Modify Tx

capivasertib + ivacaftor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ixabepilone
Truqap (capivasertib)

+

ixabepilone

1 interaction

Monitor/Modify Tx

capivasertib + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• kratom
Truqap (capivasertib)

+

kratom

1 interaction

Monitor/Modify Tx

capivasertib + kratom

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lapatinib
Truqap (capivasertib)

+

lapatinib

1 interaction

Monitor/Modify Tx

capivasertib + lapatinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• larotrectinib
Truqap (capivasertib)

+

larotrectinib

1 interaction

Monitor/Modify Tx

capivasertib + larotrectinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lazertinib
Truqap (capivasertib)

+

lazertinib

1 interaction

Monitor/Modify Tx

capivasertib + lazertinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lefamulin
Truqap (capivasertib)

+

lefamulin

1 interaction

Monitor/Modify Tx

capivasertib + lefamulin

ORAL LEFAMULIN: monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off; IV lefamulin use OK: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lemborexant
Truqap (capivasertib)

+

lemborexant

1 interaction

Monitor/Modify Tx

capivasertib + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• letermovir
Truqap (capivasertib)

+

letermovir

1 interaction

Monitor/Modify Tx

capivasertib + letermovir

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• linagliptin
Truqap (capivasertib)

+

linagliptin

1 interaction

Monitor/Modify Tx

capivasertib + linagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Truqap (capivasertib)

+

liraglutide

1 interaction

Monitor/Modify Tx

capivasertib + liraglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lomitapide
Truqap (capivasertib)

+

lomitapide

1 interaction

Monitor/Modify Tx

capivasertib + lomitapide

monitor glucose; max lomitapide dose 30 mg/day: combo may incr. levels of both drugs, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lovastatin
Truqap (capivasertib)

+

lovastatin

1 interaction

Monitor/Modify Tx

capivasertib + lovastatin

monitor glucose, CK, myopathy sx: combo may incr. levels of both drugs, risk of severe hyperglycemia, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lumateperone
Truqap (capivasertib)

+

lumateperone

1 interaction

Monitor/Modify Tx

capivasertib + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurasidone
Truqap (capivasertib)

+

lurasidone

1 interaction

Monitor/Modify Tx

capivasertib + lurasidone

monitor ECG, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• lurbinectedin
Truqap (capivasertib)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

capivasertib + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• maribavir
Truqap (capivasertib)

+

maribavir

1 interaction

Monitor/Modify Tx

capivasertib + maribavir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• mavorixafor
Truqap (capivasertib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

capivasertib + mavorixafor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• metformin
Truqap (capivasertib)

+

metformin

1 interaction

Monitor/Modify Tx

capivasertib + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• metoprolol
Truqap (capivasertib)

+

metoprolol

1 interaction

Monitor/Modify Tx

capivasertib + metoprolol

monitor BP, HR; consider lower metoprolol dose: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited)

• midazolam
Truqap (capivasertib)

+

midazolam

1 interaction

Monitor/Modify Tx

capivasertib + midazolam

monitor resp. rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• miglitol
Truqap (capivasertib)

+

miglitol

1 interaction

Monitor/Modify Tx

capivasertib + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• mobocertinib
Truqap (capivasertib)

+

mobocertinib

1 interaction

Monitor/Modify Tx

capivasertib + mobocertinib

monitor ECG: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• nateglinide
Truqap (capivasertib)

+

nateglinide

1 interaction

Monitor/Modify Tx

capivasertib + nateglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• nebivolol
Truqap (capivasertib)

+

nebivolol

1 interaction

Monitor/Modify Tx

capivasertib + nebivolol

monitor BP, HR: combo may incr. nebivolol levels, risk of hypotension, bradycardia, other adverse effects (hepatic metab. inhibited)

• netupitant
Truqap (capivasertib)

+

netupitant

1 interaction

Monitor/Modify Tx

capivasertib + netupitant

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off during and x1wk after (fos)netupitant tx: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• nicardipine
Truqap (capivasertib)

+

nicardipine

1 interaction

Monitor/Modify Tx

capivasertib + nicardipine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• nifedipine
Truqap (capivasertib)

+

nifedipine

1 interaction

Monitor/Modify Tx

capivasertib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nilotinib
Truqap (capivasertib)

+

nilotinib

1 interaction

Monitor/Modify Tx

capivasertib + nilotinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• nimodipine
Truqap (capivasertib)

+

nimodipine

1 interaction

Monitor/Modify Tx

capivasertib + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nirogacestat
Truqap (capivasertib)

+

nirogacestat

1 interaction

Monitor/Modify Tx

capivasertib + nirogacestat

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Truqap (capivasertib)

+

nisoldipine

1 interaction

Monitor/Modify Tx

capivasertib + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nortriptyline
Truqap (capivasertib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

capivasertib + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metab. inhibited)

• osilodrostat
Truqap (capivasertib)

+

osilodrostat

1 interaction

Monitor/Modify Tx

capivasertib + osilodrostat

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• palbociclib
Truqap (capivasertib)

+

palbociclib

1 interaction

Monitor/Modify Tx

capivasertib + palbociclib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• pazopanib
Truqap (capivasertib)

+

pazopanib

1 interaction

Monitor/Modify Tx

capivasertib + pazopanib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• pemigatinib
Truqap (capivasertib)

+

pemigatinib

1 interaction

Monitor/Modify Tx

capivasertib + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• peppermint
Truqap (capivasertib)

+

peppermint

1 interaction

Monitor/Modify Tx

capivasertib + peppermint

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• perphenazine
Truqap (capivasertib)

+

perphenazine

1 interaction

Monitor/Modify Tx

capivasertib + perphenazine

consider decr. perphenazine dose: combo may incr. perphenazine levels, risk of adverse effects (hepatic metab. inhibited)

• pibrentasvir
Truqap (capivasertib)

+

pibrentasvir

1 interaction

Monitor/Modify Tx

capivasertib + pibrentasvir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• pioglitazone
Truqap (capivasertib)

+

pioglitazone

1 interaction

Monitor/Modify Tx

capivasertib + pioglitazone

monitor glucose: combo may decr. capivasertib levels, efficacy; may decr. antidiabetic agent efficacy (hepatic metab. induced; antagonistic effects)

• pirtobrutinib
Truqap (capivasertib)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

capivasertib + pirtobrutinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• pitolisant
Truqap (capivasertib)

+

pitolisant

1 interaction

Monitor/Modify Tx

capivasertib + pitolisant

monitor ECG: combo may incr. pitolisant levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pramlintide
Truqap (capivasertib)

+

pramlintide

1 interaction

Monitor/Modify Tx

capivasertib + pramlintide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• propranolol
Truqap (capivasertib)

+

propranolol

1 interaction

Monitor/Modify Tx

capivasertib + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited)

• quercetin
Truqap (capivasertib)

+

quercetin

1 interaction

Monitor/Modify Tx

capivasertib + quercetin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• quinidine (antiarrhythmic)
Truqap (capivasertib)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

capivasertib + quinidine (antiarrhythmic)

monitor quinidine levels: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ranolazine
Truqap (capivasertib)

+

ranolazine

1 interaction

Monitor/Modify Tx

capivasertib + ranolazine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• red yeast rice
Truqap (capivasertib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

capivasertib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• remdesivir
Truqap (capivasertib)

+

remdesivir

1 interaction

Monitor/Modify Tx

capivasertib + remdesivir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• repaglinide
Truqap (capivasertib)

+

repaglinide

1 interaction

Monitor/Modify Tx

capivasertib + repaglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• resveratrol
Truqap (capivasertib)

+

resveratrol

1 interaction

Monitor/Modify Tx

capivasertib + resveratrol

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ritlecitinib
Truqap (capivasertib)

+

ritlecitinib

1 interaction

Monitor/Modify Tx

capivasertib + ritlecitinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• rosiglitazone
Truqap (capivasertib)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

capivasertib + rosiglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rucaparib
Truqap (capivasertib)

+

rucaparib

1 interaction

Monitor/Modify Tx

capivasertib + rucaparib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• saxagliptin
Truqap (capivasertib)

+

saxagliptin

1 interaction

Monitor/Modify Tx

capivasertib + saxagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• selpercatinib
Truqap (capivasertib)

+

selpercatinib

1 interaction

Monitor/Modify Tx

capivasertib + selpercatinib

monitor ECG, electrolytes, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• selumetinib
Truqap (capivasertib)

+

selumetinib

1 interaction

Monitor/Modify Tx

capivasertib + selumetinib

monitor LVEF, CK, myopathy sx: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• semaglutide
Truqap (capivasertib)

+

semaglutide

1 interaction

Monitor/Modify Tx

capivasertib + semaglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sirolimus
Truqap (capivasertib)

+

sirolimus

1 interaction

Monitor/Modify Tx

capivasertib + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited)

• sirolimus albumin-bound
Truqap (capivasertib)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

capivasertib + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• sitagliptin
Truqap (capivasertib)

+

sitagliptin

1 interaction

Monitor/Modify Tx

capivasertib + sitagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• spironolactone
Truqap (capivasertib)

+

spironolactone

1 interaction

Monitor/Modify Tx

capivasertib + spironolactone

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. possibly inhibited)

• stiripentol
Truqap (capivasertib)

+

stiripentol

1 interaction

Monitor/Modify Tx

capivasertib + stiripentol

monitor glucose: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metab. altered)

• sufentanil
Truqap (capivasertib)

+

sufentanil

1 interaction

Monitor/Modify Tx

capivasertib + sufentanil

monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tacrolimus
Truqap (capivasertib)

+

tacrolimus

1 interaction

Monitor/Modify Tx

capivasertib + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited)

• tadalafil
Truqap (capivasertib)

+

tadalafil

1 interaction

Monitor/Modify Tx

capivasertib + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• temsirolimus
Truqap (capivasertib)

+

temsirolimus

1 interaction

Monitor/Modify Tx

capivasertib + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• tetrabenazine
Truqap (capivasertib)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

capivasertib + tetrabenazine

consider decr. tetrabenazine dose: combo may incr. tetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ticagrelor
Truqap (capivasertib)

+

ticagrelor

1 interaction

Monitor/Modify Tx

capivasertib + ticagrelor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• tirzepatide
Truqap (capivasertib)

+

tirzepatide

1 interaction

Monitor/Modify Tx

capivasertib + tirzepatide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tolvaptan
Truqap (capivasertib)

+

tolvaptan

1 interaction

Monitor/Modify Tx

capivasertib + tolvaptan

monitor glucose; consider decr. tolvaptan dose: combo may incr. levels of both drugs, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• treosulfan
Truqap (capivasertib)

+

treosulfan

1 interaction

Monitor/Modify Tx

capivasertib + treosulfan

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. possibly inhibited)

• triazolam
Truqap (capivasertib)

+

triazolam

1 interaction

Monitor/Modify Tx

capivasertib + triazolam

monitor resp. rate: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• trofinetide
Truqap (capivasertib)

+

trofinetide

1 interaction

Monitor/Modify Tx

capivasertib + trofinetide

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• ubrogepant
Truqap (capivasertib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

capivasertib + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited)

• vardenafil
Truqap (capivasertib)

+

vardenafil

1 interaction

Monitor/Modify Tx

capivasertib + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• venetoclax
Truqap (capivasertib)

+

venetoclax

1 interaction

Monitor/Modify Tx

capivasertib + venetoclax

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• verapamil
Truqap (capivasertib)

+

verapamil

1 interaction

Monitor/Modify Tx

capivasertib + verapamil

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• viloxazine
Truqap (capivasertib)

+

viloxazine

1 interaction

Monitor/Modify Tx

capivasertib + viloxazine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• vinblastine
Truqap (capivasertib)

+

vinblastine

1 interaction

Monitor/Modify Tx

capivasertib + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• vincristine
Truqap (capivasertib)

+

vincristine

1 interaction

Monitor/Modify Tx

capivasertib + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Truqap (capivasertib)

+

vinorelbine

1 interaction

Monitor/Modify Tx

capivasertib + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vonoprazan
Truqap (capivasertib)

+

vonoprazan

1 interaction

Monitor/Modify Tx

capivasertib + vonoprazan

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• voxelotor
Truqap (capivasertib)

+

voxelotor

1 interaction

Monitor/Modify Tx

capivasertib + voxelotor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• warfarin
Truqap (capivasertib)

+

warfarin

1 interaction

Monitor/Modify Tx

capivasertib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• xanomeline
Truqap (capivasertib)

+

xanomeline

1 interaction

Monitor/Modify Tx

capivasertib + xanomeline

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metab. possibly inhibited)

• yohimbe
Truqap (capivasertib)

+

yohimbe

1 interaction

Monitor/Modify Tx

capivasertib + yohimbe

monitor BP, HR: combo may incr. yohimbe levels, risk of HTN, tachycardia, other adverse effects (hepatic metab. inhibited)

• zanubrutinib
Truqap (capivasertib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

capivasertib + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• zileuton
Truqap (capivasertib)

+

zileuton

1 interaction

Monitor/Modify Tx

capivasertib + zileuton

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)